AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
AEZS has been the subject of several other research reports. ValuEngine raised AEterna Zentaris from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd. HC Wainwright reaffirmed a “buy” rating on shares of AEterna Zentaris in a research report on Thursday, January 17th. Finally, Maxim Group set a $2.00 target price on AEterna Zentaris and gave the stock a “buy” rating in a research report on Thursday, December 20th. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $2.67.
AEZS opened at $3.96 on Friday. The firm has a market cap of $65.10 million, a PE ratio of -2.93 and a beta of 1.23. AEterna Zentaris has a fifty-two week low of $1.12 and a fifty-two week high of $4.39.
Institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of AEterna Zentaris in the fourth quarter worth $30,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of AEterna Zentaris in the fourth quarter worth $66,000. Acadian Asset Management LLC boosted its position in shares of AEterna Zentaris by 27.2% in the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 9,640 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of AEterna Zentaris in the third quarter worth $101,000. 15.31% of the stock is owned by institutional investors and hedge funds.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Article: The mechanics of the bid-ask spread in trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.